Pasithea Therapeutics
Market cap $16.0M 36.8M shares (10-Q, Nov 12, 2026) × $0.434 close Nov 17, 2026
Most recent annual filing: 2026-03-30
Pipeline (4 active programs)
PAS-001
Discontinued (1)
- PAS-003 — Amyotrophic Lateral Sclerosis · ceased further development due to significant capital, resources and time required to develop the program
Capital (as filed)
- Cash
- $41.2M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Operating cash flow
- −$4.5M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $41.2M cash per the update of Nov 13, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (5)
- 2026-11-14 UPDATE: Pasithea Therapeutics (KTTA) - The Marquee Event Lands on the Skin 🔒 Paid
- 2026-11-04 UPDATE: Pasithea Therapeutics (KTTA) - The Second Front Opens ★ Distilled Pro
- 2026-06-30 UPDATE: Pasithea Therapeutics (KTTA) - The Macrocycle Earns Its Keep 🔒 Paid
- 2026-06-16 UPDATE: Pasithea Therapeutics (KTTA) - The Protocol Amendment Tax 🔒 Paid
- 2026-05-16 Pasithea Therapeutics (KTTA) - Scientific Deep Dive for PAS-004 and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (5 calls)
Every verdict Biotech Distilled has published on Pasithea Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-05-16 Buy core Pasithea Therapeutics (KTTA) - Scientific Deep Dive for PAS-004 and Pipeline Products Clean event-driven setup with elegant macrocycle chemistry, dilution-proof balance sheet through 1H 2028, and catalyst-rich 2H 2026 NF1-PN readout makes KTTA attractive for accumulation ahead of the data run.
- 2026-06-16 Buy core UPDATE: Pasithea Therapeutics (KTTA) - The Protocol Amendment Tax Macrocycle thesis intact with no safety signal or balance-sheet shock; 34.6% drawdown reflects timing re-pricing from protocol amendment rather than thesis breakage, so BUY is maintained despite degraded catalyst geometry.
- 2026-06-30 Buy core UPDATE: Pasithea Therapeutics (KTTA) - The Macrocycle Earns Its Keep Cancer trial interim confirms macrocycle PK advantage translates to chronic clinical tolerability with durable disease control in BRAF/MEK-pretreated patients, strengthening the thesis ahead of the Q4 NF1 interim.
- 2026-11-04 Buy core UPDATE: Pasithea Therapeutics (KTTA) - The Second Front Opens FDA IND clearance for a randomized placebo-controlled Phase 2 in NF1-cNF opens a second indication with no approved systemic competitor, playing directly to the macrocycle's chronic-tolerability edge and modestly increasing M&A appeal.
- 2026-11-14 Buy core UPDATE: Pasithea Therapeutics (KTTA) - The Marquee Event Lands on the Skin 15/15 cNF responders with 46% median reduction at Phase 2 doses in an indication with no approved systemic competitor strengthens the thesis, though a likely financing and Nasdaq compliance overhang prevent an upgrade.
- Long call · opened May 18, 2026 at $0.770 · -43.6% vs XBI +13.8% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Filings & releases (23)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Jun 2, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 16, 20268-KCurrent report: Reg FD disclosure · EX-99.1 PRESS RELEASE DATED NOVEMBER 13, 2026
- Nov 13, 2026ReleasePasithea Therapeutics Presents Positive Initial Phase 1/1b Data for PAS-004, Showing Substantial Reductions in Cutaneous Neurofibroma Size and Early Activity in Plexiform Neurofibromas at the 2026 Eur→ BD updateSummary on the 10-Q
- Nov 13, 202610-QQuarterly report→ BD updateThe macrocycle just delivered its first real NF1 efficacy readout: 100% of evaluable cNF patients shrank, with median 41% tumor reduction and responses deepening to 71% at 15 months — no approved systemic competitor, no safety showstoppers, and a Phase 2 already IND-cleared to capitalize on it.
- Nov 3, 2026ReleasePasithea Therapeutics Announces FDA Clearance of IND for PAS-004 in Neurofibromatosis Type 1 (NF1)-Associated Cutaneous Neurofibromas (cNF)→ BD updateThe FDA has cleared an IND for a randomized, placebo-controlled Phase 2 trial of PAS-004 in NF1-associated cutaneous neurofibromas — a 80,000-patient indication with zero approved systemic therapies, and the exact "label-expansion seed" I flagged in June.
- Oct 28, 2026ReleasePasithea Therapeutics to Host Virtual KOL Event on NF1 Treatment November 4, 2026
- Oct 23, 2026ReleasePasithea Therapeutics Announces Positive PAS-004 Clinical Data from Phase 1 Advanced Cancer Study Presented at ESMO Congress 2026BD extracted 1 program update from this document → KTTA pipeline
- Sep 16, 20268-KCurrent report: other events
- Sep 16, 202625-NSEDelisting notice
- Sep 14, 2026ReleasePasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis ConferenceBD extracted 1 program update from this document → KTTA pipeline
- Sep 9, 20268-KCurrent report: shareholder vote
- Sep 3, 2026ReleasePasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences
- Aug 21, 20268-KCurrent report: listing notice
- Aug 14, 202610-QQuarterly report
- Aug 7, 2026DEF 14AProxy statement
- Jul 21, 2026ReleasePasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026BD extracted 1 program update from this document → KTTA pipeline
- Jul 8, 2026ReleasePasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit
- Jun 30, 2026ReleasePasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus
- Jun 16, 2026ReleasePasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial
- Jun 15, 2026ReleasePasithea Therapeutics Announces Exhibit at Children’s Tumor Foundation 2026 NF Conference
- Jun 2, 2026ReleasePasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)BD extracted 2 program updates from this document → KTTA pipeline
- May 15, 202610-QQuarterly report
- May 4, 20268-KCurrent report: officer / director change, Reg FD disclosure · EX-99.1 PRESS RELEASE DATED MAY 4, 2026
- Mar 30, 202610-KAnnual report
13 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 16, 2026SCHEDULE 13G/A13G amendment
- Nov 16, 2026SCHEDULE 13G/A13G amendment
- Nov 16, 2026SCHEDULE 13G/A13G amendment
- Nov 6, 2026SCHEDULE 13G/A13G amendment
- Aug 14, 2026SCHEDULE 13G/A13G amendment
- Aug 7, 2026ARSAnnual report to shareholders
- Jul 31, 2026SCHEDULE 13G/A13G amendment
- Jul 29, 2026PRE 14APRE 14A
- Jul 1, 2026SCHEDULE 13G/A13G amendment
- Jun 23, 2026SCHEDULE 13GPassive >5% holder (13G)
- May 15, 2026SCHEDULE 13G/A13G amendment
- Apr 22, 2026SCHEDULE 13GPassive >5% holder (13G)
- Apr 8, 2026SCHEDULE 13GPassive >5% holder (13G)